Mosaic ImmunoEngineering is a nanotechnology-based immunotherapy company developing therapeutics and vaccines to positively impact the lives of patients and their families.

Free
Message: May Letter to Shareholders from Patriot Scientific President and CEO Rick Goerne

The board has this right - most shareholders understand the importance of such a move and are waiting.



The normal means to adjust the stock price to meet listing requirements would be a reverse split of the stock. The board is not anxious to move toward a reverse split until it believes that:


1. The company has a reliable, long term opportunity for growth of
(less volatile) revenues, profits and shareholder value and,

2. A reverse split will not risk a reduction of the market
capitalization of the company.

Again, no definitive timeline has been outlined for considering
these actions, but I believe that the shareholders understand the
company's objectives, and perspectives, with respect to these possible actions.

Share
New Message
Please login to post a reply